The company recently presented its Manufacturing Execution System, Huraflow-MES, to the National Agency for Food and Drug Administration and Control (NAFDAC) at the regulator’s operational headquarters, signalling the start of what could become a strategic collaboration to digitise critical processes within the industry.
Huraflow-MES is positioned as an integrated platform that connects the key components of manufacturing—materials, machines, manpower, and methods—into a single digital ecosystem. By doing so, it enables real-time monitoring, improved traceability, and enhanced compliance with regulatory standards across pharmaceutical and fast-moving consumer goods (FMCG) production.
According to Symmex, the solution was developed in response to persistent gaps in the sector, where many manufacturers still rely heavily on manual, paper-based processes. This reliance has long posed challenges for both operational efficiency and regulatory supervision.
The platform also addresses a structural imbalance faced by regulators such as NAFDAC, whose oversight responsibilities continue to expand alongside rapid industry growth. With limited manpower and resources, traditional inspection methods often struggle to keep pace.
Huraflow-MES introduces a remote inspection capability that allows regulators to access manufacturers’ electronic records ahead of physical visits. This approach enables more targeted inspections, allowing authorities to focus on high-risk areas rather than relying solely on periodic on-site reviews.
Beyond regulatory efficiency, the system is designed to enhance patient safety. Its digital audit trails are tamper-evident, making it easier to trace production issues and conduct investigations. In cases of product defects or contamination, manufacturers and regulators can quickly isolate affected batches, significantly reducing response time for recalls and corrective actions.
Symmex is also expanding its technological ambitions beyond manufacturing execution. The company revealed ongoing development of an artificial intelligence-driven platform, ONÍSÈGÙN AI, aimed at transforming pharmaceutical research and formulation. The tool is expected to help local manufacturers simulate drug formulations, cutting down reliance on imported licences from markets such as India, China, and Europe.
By incorporating local environmental variables—such as Nigeria’s high humidity—into its simulations, the platform could improve drug stability and shelf life, a critical factor in ensuring product quality in tropical climates.
Industry response to the Huraflow-MES platform has reportedly been positive, though widespread adoption is likely to depend on regulatory alignment and endorsement. Symmex emphasised that its engagement with NAFDAC is not purely commercial but aimed at supporting the agency’s mandate to safeguard public health.
From a technical standpoint, the platform is designed to simplify manufacturing workflows while strengthening compliance processes. By reducing reliance on paper documentation and enabling real-time access to operational data, it offers both manufacturers and regulators a more efficient and transparent system.
The company indicated that further discussions with NAFDAC’s leadership are planned, as it seeks to align the platform with regulatory frameworks and accelerate its deployment across Nigeria’s pharmaceutical and FMCG sectors.
If implemented at scale, solutions like Huraflow-MES could mark a significant step toward digitising Nigeria’s manufacturing ecosystem—enhancing regulatory effectiveness, improving product safety, and positioning local producers for greater competitiveness in global markets.